Search hospitals > California > Los Angeles
USC / Norris Comprehensive Cancer Center
Claim this profileLos Angeles, California 90033
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
960 reported clinical trials
63 medical researchers
Summary
USC / Norris Comprehensive Cancer Center is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Tumors, Breast Cancer, Lung Cancer, Colorectal Cancer and other specialties. USC / Norris Comprehensive Cancer Center is involved with conducting 960 clinical trials across 753 conditions. There are 63 research doctors associated with this hospital, such as Anthony El-Khoueiry, MD, Heinz-Josef Lenz, David Hong, MD, and Jacob Thomas, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Tumors
Global LeaderStage IV
Stage III
Stage I
Top PIs
Anthony El-Khoueiry, MDUSC Norris Comprehensive Cancer Center1 year of reported clinical research
Expert in Tumors
Expert in Solid Tumors
34 reported clinical trials
51 drugs studied
Heinz-Josef LenzUSC / Norris Comprehensive Cancer Center3 years of reported clinical research
Expert in Colorectal Cancer
Expert in Adenocarcinoma
32 reported clinical trials
59 drugs studied
David Hong, MDM D Anderson Cancer Center3 years of reported clinical research
Expert in Tumors
Expert in Solid Tumors
22 reported clinical trials
43 drugs studied
Jacob Thomas, MDUSC Norris Comprehensive Cancer Center1 year of reported clinical research
Studies Cancer
Studies Oral Squamous Cell Carcinoma
22 reported clinical trials
32 drugs studied
Clinical Trials running at USC / Norris Comprehensive Cancer Center
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Pancreatic Cancer
Skin Cancer
Colorectal Cancer
Squamous Cell Carcinoma
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: are 18 years of age or older; are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; have advanced or metastatic breast cancer after taking other treatments before this study; have not taken or need to take medications that are not allowed by the study protocol; do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: Fulvestrant alone taken as shot into the muscle. Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. the study doctor thinks the participant is no longer benefitting from the study medicine. has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at USC / Norris Comprehensive Cancer Center?
USC / Norris Comprehensive Cancer Center is a medical facility located in Los Angeles, California. This center is recognized for care of Cancer, Tumors, Breast Cancer, Lung Cancer, Colorectal Cancer and other specialties. USC / Norris Comprehensive Cancer Center is involved with conducting 960 clinical trials across 753 conditions. There are 63 research doctors associated with this hospital, such as Anthony El-Khoueiry, MD, Heinz-Josef Lenz, David Hong, MD, and Jacob Thomas, MD.
Where is USC / Norris Comprehensive Cancer Center located?
**USC Norris Comprehensive Cancer Center Location and Access:**
- Address: 1441 Eastlake Ave, Los Angeles, CA 90033.
- By Car: Accessible via I-10 W or I-110 S, exit at Exposition Blvd, proceed north on S Park View St, and turn right onto Elaine Ave.
- Public Transportation: For routes and schedules, refer to Moovit for guidance from your specific location.
Who should I call to ask about financial aid or insurance network?
For financial assistance at USC Norris Comprehensive Cancer Center, contact the Business Office at (323) 865-3000 or email uscnorrisinfo@med.usc.edu. For insurance inquiries, use the same contact details. The Financial Assistance Program at Keck Medicine of USC, including USC Norris Hospital, is reachable at (855) 532-5729 or through their website for more details and forms.
What insurance does USC / Norris Comprehensive Cancer Center accept?
The USC Norris Comprehensive Cancer Center accepts a wide range of insurance plans, including but not limited to Aetna Healthcare, Anthem Blue Cross, Blue Shield of California, CIGNA, and United Healthcare. It's advised to verify benefits and network providers for specific products with your health plan, as not all providers participate in all health plan products or networks. The USC Trojan Care EPO and USC PPO plans specifically provide access to Keck Medicine of USC providers, including the USC Norris Comprehensive Cancer Center.
What awards or recognition has USC / Norris Comprehensive Cancer Center received?
The USC Norris Comprehensive Cancer Center, an NCI-designated comprehensive cancer center, is dedicated to reducing cancer health disparities in underserved communities, supported by a $25 million grant from The Ralph Lauren Corporate Foundation. It leads in cancer treatment and translates scientific discoveries into innovative therapies for patients.